Additional File 1 of Identification and Validation of Stemness-Related Lncrna Prognostic Signature for Breast Cancer

Xiaoying Li,Li Yang,Xinmiao Yu,Feng Jin

DOI: https://doi.org/10.6084/m9.figshare.12900653

2020-01-01

Abstract:Additional file 1. The list of 1198 BCSC-related lncRNAs.

What problem does this paper attempt to address?

Additional File 2 of Identification and Validation of Stemness-Related Lncrna Prognostic Signature for Breast Cancer

Xiaoying Li,Li Yang,Xinmiao Yu,Feng Jin

DOI: https://doi.org/10.6084/m9.figshare.12900656

2020-01-01

Abstract:Additional file 2. The list of 213 BCSC-related mRNAs.
ZGRF1 is Associated with Poor Prognosis in Triple-Negative Breast Cancer and Promotes Cancer Stemness Based on Bioinformatics.

Weiyu Ge,Mengyi Jiang,Fengchun Zhang,Yue Ma,Hongxia Wang,Yingchun Xu

DOI: https://doi.org/10.2147/ott.s234250

IF: 4

2020-01-01

OncoTargets and Therapy

Abstract:Background: Recently, long non-coding RNAs (lncRNAs) are important populations of noncoding RNAs with defined key roles in normal breast development as well as breast tumorigenesis. Triple-negative breast cancer (TNBC) is a particular breast cancer subtype with poor prognosis because of highly invasive and no specific drug treatment yet. Breast cancer stems cells (BCSCs) cause a high risk of invasion, metastasis and drug resistance for breast cancer patients. Methods: Two microarrays of BCSCs and no-BCSCs were isolated from mammosphere-3D-cultured MCF-7 cells, differentially expressed lncRNAs (DELs) were screened out by Gene Expression Omnibus (GEO). Gene ontology enrichment analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were also performed to analyze DELs features. Using the STRING database to analyze DELs interaction network module to further screen the hub lncRNAs related to tumor stemness and make functional annotations. The expressions of hub DELs were validated using data from The Cancer Genome Atlas database. In addition, the expression analysis and survival analysis were conducted using GEO was utilized to analyze DELs in TNBC using GEPIA database. Results: A total of 143 aberrantly expressed lncRNAs in BCSCs were identified, and 25 lncRNAs were downregulated and 118 lncRNAs were upregulated compared to non-BCSCs. Up- and downregulated top 3 lncRNAs were selected and verified by RT-PCR. Notably, GO enrichment analysis and KEGG pathway analysis indicated that RNA transport, spliceosome, oxidative phosphorylation, NOD-like receptor signaling pathway, PI3K-Akt signaling pathway, and metabolic pathways may serve important roles in BCSCs. Additionally, the function loss assay indicated that ZGRF1 positively upregulated phenotype and biological functions of BCSCs in vitro. Collectively, our work establishes the lncRNAs signature in BCSCs and these findings assess us with evidence to explore further functionalities of lncRNAs in BCSCs and provide a novel therapeutic strategy for breast cancer. Conclusion: Our work establishes the lncRNAs signature in BCSCs and these findings assess us with evidence to explore further functionalities of lncRNAs in BCSCs and provide a novel therapeutic strategy for breast cancer. ZGRF1 expression is upregulated in TNBC patients and has a poor prognosis, which can be promising biomarkers.
Development and Validation of a Novel Stemness-Index-Related Long Noncoding RNA Signature for Breast Cancer Based on Weighted Gene Co-Expression Network Analysis

Da Qian,Cheng Qian,Buyun Ye,Ming Xu,Danping Wu,Jialu Li,Dong Li,Bin Yu,Yijing Tao

DOI: https://doi.org/10.3389/fgene.2022.760514

IF: 3.7

2022-02-22

Frontiers in Genetics

Abstract:Background: Breast cancer (BC) is a major leading cause of woman deaths worldwide. Increasing evidence has revealed that stemness features are related to the prognosis and progression of tumors. Nevertheless, the roles of stemness-index-related long noncoding RNAs (lncRNAs) in BC remain unclear. Methods: Differentially expressed stemness-index-related lncRNAs between BC and normal samples in The Cancer Genome Atlas database were screened based on weighted gene co-expression network analysis and differential analysis. Univariate Cox and least absolute shrinkage and selection operator regression analyses were performed to identify prognostic lncRNAs and construct a stemness-index-related lncRNA signature. Time-dependent receiver operating characteristic curves were plotted to evaluate the predictive capability of the stemness-index-related lncRNA signature. Moreover, correlation analysis and functional enrichment analyses were conducted to investigate the stemness-index-related lncRNA signature-related biological function. Finally, a quantitative real-time polymerase chain reaction was used to detect the expression levels of lncRNAs. Results: A total of 73 differentially expressed stemness-index-related lncRNAs were identified. Next, FAM83H-AS1, HID1-AS1, HOXB-AS1, RP11-1070N10.3, RP11-1100L3.8, and RP11-696F12.1 were used to construct a stemness-index-related lncRNA signature, and receiver operating characteristic curves indicated that stemness-index-related lncRNA signature could predict the prognosis of BC well. Moreover, functional enrichment analysis suggested that differentially expressed genes between the high-risk group and low-risk group were mainly involved in immune-related biological processes and pathways. Furthermore, functional enrichment analysis of lncRNA-related protein-coding genes revealed that FAM83H-AS1, HID1-AS1, HOXB-AS1, RP11-1070N10.3, RP11-1100L3.8, and RP11-696F12.1 were associated with neuroactive ligand–receptor interaction, AMPK signaling pathway, PPAR signaling pathway, and cGMP-PKG signaling pathway. Finally, quantitative real-time polymerase chain reaction revealed that FAM83H-AS1, HID1-AS1, RP11-1100L3.8, and RP11-696F12.1 might be used as the potential diagnostic biomarkers of BC. Conclusion: The stemness-index-related lncRNA signature based on FAM83H-AS1, HID1-AS1, HOXB-AS1, RP11-1070N10.3, RP11-1100L3.8, and RP11-696F12.1 could be used as an independent predictor for the survival of BC, and FAM83H-AS1, HID1-AS1, RP11-1100L3.8, and RP11-696F12.1 might be used as the diagnostic markers of BC.

genetics & heredity
Identification of Glycolysis-Associated Long Non-Coding RNA Regulatory Subtypes and Construction of Prognostic Signatures by Transcriptomics for Bladder Cancer

Mao Chenyu,Gao Yuan,Wan Mingyu,Xu Nong

DOI: https://doi.org/10.1007/s10142-022-00845-9

2022-01-01

Functional & Integrative Genomics

Abstract:Glycolysis-targeted cancer therapy based on long non-coding RNAs (lncRNAs), owing to its high specificity and less toxicity, is at the preclinical stages. Our study aimed to examine the roles of the core glycolysis-associated lncRNAs in bladder cancer (BC). Glycolysis scores of BC were computed by single-sample gene set enrichment analysis (ssGSEA). Glycolysis-associated lncRNAs were screened by Pearson's correlation analysis. Unsupervised consensus clustering using ConsensusClusterPlus assessed the glycolysis-associated lncRNAs for the identification of molecular subtypes of BC. The Kaplan-Meier survival analysis, genomic mutations, and tumor microenvironment (TME) analysis were used to compare the characteristics of different subtypes. Key glycolysis-associated lncRNAs were screened by first-order partial correlation and univariate Cox proportional-hazards model analyses; finally, the lncRNA signature was constructed. Four glycolysis-associated lncRNA-regulated subtypes having differential overall survival (OS), clinical features, genomic mutation profiles, and TME profiles along with nuclear immunotherapeutic responses were identified. Nine lncRNAs localized in the nucleus were identified and transcription factors (TFs) significantly negatively associated with these were found to be enriched in multiple oncogenic signaling pathways. Among them, three lncRNAs (AC093673.5, AC034220.3, and RP11-250B2.3) exerted the most profound effects on glycolysis and constituted the lncRNA signature, which could substantially distinguish the risk levels among different BC patients. Four glycolysis-associated lncRNA-regulated subtypes were identified in this study, reflective of the biological characteristics and heterogeneity of BC. Three key glycolysis-associated lncRNA constituting a signature could predict the risk levels in BC, provide a reference for stratification, and be used as prognostic markers for BC diagnosis and treatment.
Additional File 2 of A Novel Signature of Two Long Non-Coding RNAs in BRCA Mutant Ovarian Cancer to Predict Prognosis and Efficiency of Chemotherapy

Yinglian Pan,Jia Li,Yuzhu Liu,Yiyu Han,Qian Li,Qin Zou,Zhongpei Zhang,Haiming Jin,Qingchun Deng

DOI: https://doi.org/10.6084/m9.figshare.12980277

2020-01-01

Abstract:Additional file 2: Table S1. Differentially expressed mRNAs and lncRNAs.
Identification of a Six-Immune-Related Long Non-coding RNA Signature for Predicting Survival and Immune Infiltrating Status in Breast Cancer

Zheng Li,Yaming Li,Xiaolong Wang,Qifeng Yang

DOI: https://doi.org/10.3389/fgene.2020.00680

IF: 3.7

2020-07-07

Frontiers in Genetics

Abstract:Long non-coding RNAs (lncRNAs) play critical roles in tumor immunity; however, the functional roles of immune-related lncRNAs in breast cancer (BC) remain elusive. To further explore the immune−related lncRNAs in BC, whole genomic expression data and corresponding clinical information were obtained from multiple BC datasets. Based on correlation with the immune-related genes within the training set, we screened out the most promising immune-related lncRNAs. Subsequently, Lasso penalized Cox regression analysis followed by stepwise multivariate Cox regression analysis identified six survival-related lncRNAs (AC116366.1, AC244502.1, AC100810.1, MIAT, AC093297.2, and AL356417.2) and constructed a prognostic signature. The cohorts in the high−risk group had significantly poor survival time compared to those in the low−risk group. In addition, a nomogram integrated with clinical features and the prognostic signature was developed on the basis of the training set. Importantly, all the findings had a similar performance in three validated datasets. In the following studies, our integrative analyses indicated that the infiltration of CD8-positive (CD8) T cells associated with a good prognosis was strikingly activated in the low−risk group. To further provide an interpretation of biological mechanisms for the prognostic signature, we performed weighted gene co−expression network analysis (WGCNA) followed by KEGG pathway-enrichment analysis. Our results showed that the antigen presentation pathway involved in protein processing in endoplasmic reticulum and antigen processing and presentation was markedly altered in the high-risk group, which might promote tumor immune evasion and associate with poor clinical outcomes in BC patients with high risk scores. In conclusion, we aimed to take advantage of bioinformatics analyses to explore immune−related lncRNAs, which could function as prognostic indicators and promising therapeutic targets for BC patients.

genetics & heredity
Long Non-Coding RNA-based Signatures to Improve Prognostic Prediction of Breast Cancer.

Yi Zhang,Yuzhi Wang,Gang Tian,Tianhua Jiang

DOI: https://doi.org/10.1097/md.0000000000022203

IF: 1.6

2020-01-01

Medicine

Abstract:Breast cancer (BC) is a disease of high mortality rate because of high malignant, while early diagnosis and personal management may make a better prognosis possible. This study aimed to establish and validate lncRNAs signatures to improve the prognostic prediction for BC.RNA sequencing data along with the corresponding clinical information of patients with BC were gained from The Cancer Genome Atlas (TCGA). Prognostic differentially expressed lncRNAs were obtained using differentially expressed lncRNAs analysis (P value <.01 and |fold change| > 2) and univariate cox regression (P value <.05). By applying least absolute shrinkage and selection operation (LASSO) Cox regression analysis along with 10-fold cross-validation, 2 lncRNA-based signatures were constructed in the training, test and whole set.A 14-lncRNAs signature and a 10-lncRNAs signature were built for overall survival (OS) and relapse-free survival (RFS) respectively in the 3 sets. BC patients were divided into high-risk groups and low-risk groups depended on median risk score value. Significant differences were found for OS and RFS between 2 groups in the 3 sets. The time-dependent receiver operating characteristic (ROC) curves analysis demonstrated that our lncRNAs signatures had better predictive capacities of survival and recurrence for BC patients as well as enhancing the predictive ability of the tumor node metastasis (TNM) stage system.These results indicate that the 2 lncRNAs signatures with the potential to be biomarkers to predict the prognosis of BC for OS and RFS.
Additional File 2 of Identification and Validation of a Six-Gene Signature Associated with Glycolysis to Predict the Prognosis of Patients with Cervical Cancer

Luya Cai,Chuan Hu,Shanshan Yu,Lixiao Liu,Xiaobo Yu,Jiahua Chen,Xuan Li,Fan Liu,Cheng Zhang,Wenfeng Li,Xiaojian Yan

DOI: https://doi.org/10.6084/m9.figshare.13279625

2020-01-01

Abstract:Additional file 2: Table S2. The clinical information of 273 patients with CC from the UCSC database.
Additional File 5 of A Novel Signature of Two Long Non-Coding RNAs in BRCA Mutant Ovarian Cancer to Predict Prognosis and Efficiency of Chemotherapy

Yinglian Pan,Jia Li,Yuzhu Liu,Yiyu Han,Qian Li,Qin Zou,Zhongpei Zhang,Jin Long Huang,Qingchun Deng

DOI: https://doi.org/10.6084/m9.figshare.12980286

2020-01-01

Abstract:Additional file 5: Table S4. Functional enrichment analysis of different mRNAs.
Assessing the prognostic value of stemness-related genes in breast cancer patients

Wen-Jie Wang,Han Wang,Meng-sen Wang,Yue-Qing Huang,Yu-Yuan Ma,Jie Qi,Jian-Ping Shi,Wei Li

DOI: https://doi.org/10.1038/s41598-020-73164-3

IF: 4.6

2020-10-27

Scientific Reports

Abstract:Abstract Breast cancer (BC) is currently one of the deadliest tumors worldwide. Cancer stem cells (CSCs) are a small group of tumor cells with self-renewal and differentiation abilities and high treatment resistance. One of the reasons for treatment failures is the inability to completely eliminate tumor stem cells. By using the edgeR package, we identified stemness-related differentially expressed genes in GSE69280. Via Lasso-penalized Cox regression analysis and univariate Cox regression analysis, survival genes were screened out to construct a prognostic model. Via nomograms and ROC curves, we verified the accuracy of the prognostic model. We selected 4 genes ( PSMB9 , CXCL13 , NPR3 , and CDKN2C ) to establish a prognostic model from TCGA data and a validation model from GSE24450 data. We found that the low-risk score group had better OS than the high-risk score group, whether using TCGA or GSE24450 data. A prognostic model including four stemness-related genes was constructed in our study to determine targets of breast cancer stem cells (BCSCs) and improve the treatment effect.

multidisciplinary sciences
Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments

Min Zhang,Fangxu Zhang,Jianfeng Wang,Qian Liang,Weibing Zhou,Jian Liu

DOI: https://doi.org/10.1186/s12967-024-05237-0

IF: 8.44

2024-05-06

Journal of Translational Medicine

Abstract:Cancer stem cells (CSCs) and long non-coding RNAs (lncRNAs) are known to play a crucial role in the growth, migration, recurrence, and drug resistance of tumor cells, particularly in triple-negative breast cancer (TNBC). This study aims to investigate stemness-related lncRNAs (SRlncRNAs) as potential prognostic indicators for TNBC patients.

medicine, research & experimental
Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients

Xiaolong Wang,Chen Li,Tong Chen,Wenhao Li,Hanwen Zhang,Dong Zhang,Ying Liu,Dianwen Han,Yaming Li,Zheng Li,Dan Luo,Ning Zhang,Qifeng Yang

DOI: https://doi.org/10.3389/fonc.2021.660242

IF: 4.7

2021-08-26

Frontiers in Oncology

Abstract:Background Recent years, the global prevalence of breast cancer (BC) was still high and the underlying molecular mechanisms remained largely unknown. The investigation of prognosis-related biomarkers had become an urgent demand. Results In this study, gene expression profiles and clinical information of breast cancer patients were downloaded from the TCGA database. The differentially expressed genes (DEGs) were estimated by Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. A risk score formula involving five novel prognostic associated biomarkers (EDN2, CLEC3B, SV2C, WT1, and MUC2) were then constructed by LASSO. The prognostic value of the risk model was further confirmed in the TCGA entire cohort and an independent external validation cohort. To explore the biological functions of the selected genes, in vitro assays were performed, indicating that these novel biomarkers could markedly influence breast cancer progression. Conclusions We established a predictive five-gene signature, which could be helpful for a personalized management in breast cancer patients.

oncology
Identification of a Five‐lncrna Signature for Predicting the Risk of Tumor Recurrence in Patients with Breast Cancer

Jie Li,Weida Wang,Peng Xia,Linyun Wan,Li Zhang,Lei Yu,Lily Wang,Xi Chen,Yun Xiao,Chaohan Xu

DOI: https://doi.org/10.1002/ijc.31573

2018-01-01

International Journal of Cancer

Abstract:Long non-coding RNAs (lncRNAs) are a major class of non-coding RNAs, and the functional deregulations of lncRNAs have been shown to be associated with the development and progression of BC. In this work, we conduct an integrative analysis on five re-annotated lncRNA expression datasets from the Gene Expression Omnibus (GEO) which included a total of 891 BC samples. We identified a five-lncRNA signature that was significantly associated with DFS in the training cohort of 327 patients. We found the five-lncRNA signature could effectively stratify patients in the training dataset into high- and low-risk groups with significantly different DFS (p = 3.29 x 10(-5), log-rank test). The five-lncRNA signature was effectively validated in four independent cohorts, and prognostic analysis results showed that the five-lncRNA signature was independent of clinical prognostic factors, such as BC subtypes and adjuvant treatments. Furthermore, GSEA suggested that the five-lncRNA signature was involved in BC metastasis-related pathways. Our findings indicate that these five lncRNAs may be implicated in BC pathogenesis, and further, these lncRNAs may potentially serve as novel candidate biomarkers for the identification of BC patients at high risk for tumor recurrence.
Additional File 8 of Immune-related Long Non-Coding RNA Signature Identified Prognosis and Immunotherapeutic Efficiency in Bladder Cancer (BLCA)

Rui Cao,Lushun Yuan,Bo Ma,Gang Wang,Ye Tian

DOI: https://doi.org/10.6084/m9.figshare.12577466

2020-01-01

Abstract:Additional file 8: Table S3. Summary of ssGSEA scores for hallmark gene sets in TCGA-BLCA cohort.
Additional File 1 of Comprehensive Research into Prognostic and Immune Signatures of Transcription Factor Family in Breast Cancer

Qing Wu,Shiyao Zheng,Nan Lin,Xianhe Xie

DOI: https://doi.org/10.6084/m9.figshare.22697042

2023-01-01

Abstract:Additional file 1. R code and data.
Complete Identification of Autophagy-Related lncRNA Prognostic Signature for Breast Cancer

Wenxi Wang,Na Li,Lin Shen,Qin Zhou,Zhanzhan Li,Liangfang Shen

DOI: https://doi.org/10.21203/rs.3.rs-347298/v1

2021-01-01

Abstract:Abstract Purpose: Breast cancer (BC) has a relatively high morbidity and mortality for women. The research about BC prognosis is significant. Autophagy is an essential process for tumor progression, which could play its role with lncRNA, a kind of ncRNA that have regulatory roles in multiple tumors. Therefore, constructing an autophagy-related prognostic model for breast cancer is meaningful.Methods: We download data from the TCGA and HADb. Pearson correlation analysis was performed to excavate autophagy-related lncRNA. Then with gene expression difference analysis, etc. we explored the relationship between clinical features and the signature. We applied Cytoscape as well as KEGG, etc. to explore expression condition. And the autophagy status of our signature was investigated by GSEA, etc. We also searched the immune distinction by CIBERSORTx to extend our study and preliminarily verified our study in the end.Results: Firstly, we got an independent autophagy-related lncRNA prognostic model, by which BC patients were divided into high- and low-risk groups. We found that the OS of high-risk group is significantly lower than that of low-risk group, which was identical to those within various clinical subgroups. Then, the KEGG and GO analysis enriched several pathways including autophagy. PCA and GSEA analysis demonstrated the autophagy status. Several distinguishing immune cell types in separated groups were revealed by immunity analysis. Then the verification in the end proved the feasibility of our signature.Conclusion: In this study, we acquired an independent autophagy-related lncRNA signature involving 12 lncRNAs, which contributes to the prediction of prognosis of BC patients.
Systematic Analysis of Lncrna–mirna–mrna Competing Endogenous RNA Network Identifies Four-Lncrna Signature As a Prognostic Biomarker for Breast Cancer

Chun-Ni Fan,Lei Ma,Ning Liu

DOI: https://doi.org/10.1186/s12967-018-1640-2

IF: 8.44

2018-01-01

Journal of Translational Medicine

Abstract:BACKGROUND:Increasing evidence has underscored the role of long non-coding RNAs (lncRNAs) acting as competing endogenous RNAs (ceRNAs) in the development and progression of tumors. Nevertheless, lncRNA biomarkers in lncRNA-related ceRNA network that can predict the prognosis of breast cancer (BC) are still lacking. The aim of our study was to identify potential lncRNA signatures capable of predicting overall survival (OS) of BC patients.METHODS:The RNA sequencing data and clinical characteristics of BC patients were obtained from the Cancer Genome Atlas database, and differentially expressed lncRNA (DElncRNAs), DEmRNAs, and DEmiRNAs were then identified between BC and normal breast tissue samples. Subsequently, the lncRNA-miRNA-mRNA ceRNA network of BC was established, and the gene oncology enrichment analyses for the DEmRNAs interacting with lncRNAs in the ceRNA network was implemented. Using univariate and multivariate Cox regression analyses, a four-lncRNA signature was developed and used for predicting the survival in BC patients. We applied receiver operating characteristic analysis to assess the performance of our model.RESULTS:A total of 1061 DElncRNAs, 2150 DEmRNAs, and 82 DEmiRNAs were identified between BC and normal breast tissue samples. A lncRNA-miRNA-mRNA ceRNA network of BC was established, which comprised of 8 DEmiRNAs, 48 DElncRNAs, and 10 DEmRNAs. Further gene oncology enrichment analyses revealed that the DEmRNAs interacting with lncRNAs in the ceRNA network participated in cell leading edge, protease binding, alpha-catenin binding, gamma-catenin binding, and adenylate cyclase binding. A univariate regression analysis of the DElncRNAs revealed 7 lncRNAs (ADAMTS9-AS1, AC061992.1, LINC00536, HOTAIR, AL391421.1, TLR8-AS1 and LINC00491) that were associated with OS of BC patients. A multivariate Cox regression analysis demonstrated that 4 of those lncRNAs (ADAMTS9-AS1, LINC00536, AL391421.1 and LINC00491) had significant prognostic value, and their cumulative risk score indicated that this 4-lncRNA signature independently predicted OS in BC patients. Furthermore, the area under the curve of the 4-lncRNA signature associated with 3-year survival was 0.696.CONCLUSIONS:The current study provides novel insights into the lncRNA-related ceRNA network in BC and the 4 lncRNA biomarkers may be independent prognostic signatures in predicting the survival of BC patients.
Microarray to Reveal LncRNA Profile and the Role of Lnccuedc1 in BCSCs.

Fengchun Zhang,Ying Chun Xu,Ning Yan

DOI: https://doi.org/10.1200/jco.2018.36.5_suppl.3

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:3 Background: Recently, a growing amount of reports have shown that long non-coding RNAs (lncRNAs) are involved in breast cancer development, progression and metastasis. However, the correlation between lncRNAs and breast cancer stem cells (BCSCs) has been poorly explored. Methods: We initially isolated BCSCs from mammosphere-cultured cells; then, microarray analyses were carried out to detect the lncRNA signature in BCSCs. In addition, bioinformatics analyses, including Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG), were consulted to explore the functional roles of lncRNAs on BCSCs. Results: A total of 142 aberrantly expressed lncRNAs in BCSCs were identified, and of those lncRNAs, 25 were downregulated and 117 were upregulated compared to non-BCSCs. In addition, some of these lncRNAs were randomly selected and verified by RT-PCR and sanger sequencing. Notably, bioinformatics data showed that the lncRNAs that were detected were largely associated with stemness-related signalling pathways. Additionally, an interacting network between lncRNAs and its mRNAs was constructed to further depict the lncRNA functional activities. Furthermore, we found that lncCUEDC1 negatively regulated phenotype and biological functions of BCSCs in vitro. Conclusions: Our work establishes the lncRNAs signature in BCSCs for the first time. These findings provide us with evidence to explore the functionalities of lncRNAs in BCSCs and indicate that lncCUED1 is a prospective target for BCSCs.
Additional File 2 of Stemness-related LncRNA Pair Signature for Predicting Therapy Response in Gastric Cancer

Qiqi Jiang,Hao Chen,Zhaoqing Tang,Jing Sun,Yuanyuan Ruan,Fenglin Liu,Yihong Sun

DOI: https://doi.org/10.6084/m9.figshare.16703128

2021-01-01

Abstract:Additional files 2: Supplementary Table 1 (sTable 1). Stemness related genes. Supplementary Table 2 (sTable 2). 240 differentially expressed LncRNAs between 32 normal and 375 tumor RNA-seq data points. Supplementary Table 3 (sTable 3). 98 lncRNAs (88 upregulated and 10 downregulated) were identified as DEsrlncRNAs. Supplementary Table 4 (sTable 4). 760 differentially expressed genes between the low- and high-risk groups. Supplementary Table 5 (sTable 5). The results of IPS analysis for TCGA STAD.
A Novel Framework to Predict Breast Cancer Prognosis Using Immune-Associated LncRNAs

Zhijian Huang,Chen Xiao,Fushou Zhang,Zhifeng Zhou,Liang Yu,Changsheng Ye,Weiwei Huang,Nani Li

DOI: https://doi.org/10.3389/fgene.2020.634195

IF: 3.7

2021-01-21

Frontiers in Genetics

Abstract:Background: Breast cancer (BC) is one of the most frequently diagnosed malignancies among females. As a huge heterogeneity of malignant tumor, it is important to seek reliable molecular biomarkers to carry out the stratification for patients with BC. We surveyed immune- associated lncRNAs that may be used as potential therapeutic targets in BC. Methods: LncRNA expression data and clinical information of BC patients were downloaded from the TCGA database for a comprehensive analysis of candidate genes. A model consisting of immune-related lncRNAs enriched in BC cancerous tissues was established using the univariate Cox regression analysis and the iterative Lasso Cox regression analysis. The prognostic performance of this model was validated in two independent cohorts (GSE21653 and BC-KR), and compared with known prognostic biomarkers. A nomogram that integrated the immune-related lncRNA signature and clinicopathological factors was constructed to accurately assess the prognostic value of this signature. The correlation between the signature and immune cell infiltration in BC was also analyzed. Results: The Kaplan-Meier analysis showed that the OS of Patients in the low-risk group had significantly better survival than those in the high-risk group, Clinical subgroup analysis showed that the predictive ability was independent of clinicopathological factors. Univariate/multivariate Cox regression analysis showed immune lncRNA signature is an important prognostic factor and an independent prognostic marker. In addition, GSEA and GSVA analysis as well as comprehensive analysis of immune cells showed that the signature was significantly correlated with the infiltration of immune cells. Conclusion: We successfully constructed an immune-associated lncRNA signature that can accurately predict BC prognosis.

genetics & heredity

Additional File 1 of Identification and Validation of Stemness-Related Lncrna Prognostic Signature for Breast Cancer

Additional File 2 of Identification and Validation of Stemness-Related Lncrna Prognostic Signature for Breast Cancer

ZGRF1 is Associated with Poor Prognosis in Triple-Negative Breast Cancer and Promotes Cancer Stemness Based on Bioinformatics.

Development and Validation of a Novel Stemness-Index-Related Long Noncoding RNA Signature for Breast Cancer Based on Weighted Gene Co-Expression Network Analysis

Identification of Glycolysis-Associated Long Non-Coding RNA Regulatory Subtypes and Construction of Prognostic Signatures by Transcriptomics for Bladder Cancer

Additional File 2 of A Novel Signature of Two Long Non-Coding RNAs in BRCA Mutant Ovarian Cancer to Predict Prognosis and Efficiency of Chemotherapy

Identification of a Six-Immune-Related Long Non-coding RNA Signature for Predicting Survival and Immune Infiltrating Status in Breast Cancer

Long Non-Coding RNA-based Signatures to Improve Prognostic Prediction of Breast Cancer.

Additional File 2 of Identification and Validation of a Six-Gene Signature Associated with Glycolysis to Predict the Prognosis of Patients with Cervical Cancer

Additional File 5 of A Novel Signature of Two Long Non-Coding RNAs in BRCA Mutant Ovarian Cancer to Predict Prognosis and Efficiency of Chemotherapy

Assessing the prognostic value of stemness-related genes in breast cancer patients

Comprehensive characterization of stemness-related lncRNAs in triple-negative breast cancer identified a novel prognostic signature related to treatment outcomes, immune landscape analysis and therapeutic guidance: a silico analysis with in vivo experiments

Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients

Identification of a Five‐lncrna Signature for Predicting the Risk of Tumor Recurrence in Patients with Breast Cancer

Additional File 8 of Immune-related Long Non-Coding RNA Signature Identified Prognosis and Immunotherapeutic Efficiency in Bladder Cancer (BLCA)

Additional File 1 of Comprehensive Research into Prognostic and Immune Signatures of Transcription Factor Family in Breast Cancer

Complete Identification of Autophagy-Related lncRNA Prognostic Signature for Breast Cancer

Systematic Analysis of Lncrna–mirna–mrna Competing Endogenous RNA Network Identifies Four-Lncrna Signature As a Prognostic Biomarker for Breast Cancer

Microarray to Reveal LncRNA Profile and the Role of Lnccuedc1 in BCSCs.

Additional File 2 of Stemness-related LncRNA Pair Signature for Predicting Therapy Response in Gastric Cancer

A Novel Framework to Predict Breast Cancer Prognosis Using Immune-Associated LncRNAs